HOYA Vision Care Announces MiYOSMART iQ Lens with Clinical Data Showing Halt in Myopia Progression for Most Children
An end to myopia progression? In global first, new spectacle lens technology halts myopia progression in children
HOYA Vision Care and The Hong Kong Polytechnic University announced clinical trial results for the new MiYOSMART iQ spectacle lenses at ARVO 2026. The randomized controlled trial involving 196 children aged 4–12 in Hong Kong demonstrated that the lenses halted clinically relevant myopia progression for 9 out of 10 participants over 12 months. Mean spherical equivalent refractive error change was +0.046D compared to -0.534D in the control group, indicating over 100% efficacy. The design utilizes Triple Enhanced Design technology to improve defocus segments and treatment zones. While more than 15 million MiYOSMART lenses have been sold globally since 2018, HOYA notes that approval and availability of MiYOSMART iQ vary by country and are not currently available for sale in all regions, including the U.S.
The launch of MiYOSMART iQ introduces a new high-efficacy myopia control lens to the optical market, though its availability is restricted by regional regulatory approvals.
Source:HOYA Vision Care · hoyavision.com